Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

News in brief – Varian buys InfiMed. Sientra’s Silimed silicone breast implant approved. Endo changes its name. More news briefs.

You may also be interested in...



People In Brief

EOS Imaging appoints former J&J official Michael J. Dormer to be chairman. Endo Health Solutions CEO David. P. Holtech retiring. More news on device industry movers and shakers.

Financings In Brief

Sientra raises $65 million for breast implant launch. Myoscience gets $33 million. More financings.

$10 Million Needed For Inspections In China, FDA Commissioner Tells Congress

FDA is seeking an additional $10 million in fiscal 2013 for inspections of Chinese manufacturing plants and clinical trials, Commissioner Margaret Hamburg tells a House appropriations subcommittee.

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT031042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By